1.png){kind=logo}
Transforming the future of precision medicine.
#KeepYourThyroid
#SaveThyroids
#DesignToPredictBenign
GeneproDX offers an exciting investment opportunity through ThyroidPrint®, an innovative thyroid cancer diagnostic test developed in partnership with Biocartis. ThyroidPrint®'s unique decentralized model enables its global accessibility, addressing the critical need for rapid and accurate thyroid nodule diagnosis. This positions GeneproDX as a major player in the future of healthcare investment.
Our decentralized model, enabled by the Idylla™ Platform, allows testing in just 3 hours in more than 88 countries.
Market Access on five continents, including the USA.
ThyroidPrint®, as the first and currently the only test for indeterminate thyroid nodules available in Europe and LATAM, is paving the way in a market valued at US$ 2 billion per year. Our strategic plan is to consolidate our initial leadership and expand into Asia and the Middle East by 2025, to enter the U.S. market by 2025 and then Canada and Oceania by 2026.
Annually 1.25 M thyroid FNA biopsies are classified as indeterminate. In these cases, the risk of cancer is 25%, so surgery is recommended in most cases.
Approximately, 3 out of 4 surgeries on patients with indeterminate thyroid nodules are benign, resulting in an unacceptably high rate of unnecessary surgeries (900k/year globally)
In the U.S., unnecessary surgeries for indeterminate thyroid nodules cost the health care system approximately $1.26 billion per year.
At GeneproDX, we have a team of experts, complemented by advisors and board members, who guide GeneproDX's vision and ensure that our innovative approach to precision medicine reaches every corner of the world.
Executive Team
Professor of Surgery P. Universidad Católica de Chile
Santiago, Chile
Global Strategy & Operations
Barcelona, Spain
LATAM Business Development and Sales
Santiago, Chile
Board
Business Strategy Advisor
San Francisco, CA
.png)
EVP, Strategy & Corporate Development at Berkeley Lights
San Diego, CA
CEO at Family Office Girona Investment Miami, Florida
General Partner at Fondo Alerce Venture Capital
Santiago, Chile
Professor of Surgery P. Universidad Católica de Chile
Santiago, Chile
Transforming the future of precision medicine.
#KeepYourThyroid
#SaveThyroids
#DesignToPredictBenign
